{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:58:40Z","timestamp":1782572320321,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T00:00:00Z","timestamp":1585958400000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011033","name":"Thermo Fisher Scientific","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009667","name":"School of Medicine, Kyorin University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006163","name":"Project Management","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006163","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jaip.2018.11.044","type":"journal-article","created":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T18:32:04Z","timestamp":1544293924000},"page":"1287-1297.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["Long-Term Efficacy and Dose-Finding Trial of Japanese Cedar Pollen Sublingual Immunotherapy Tablet"],"prefix":"10.1016","volume":"7","author":[{"given":"Minoru","family":"Gotoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syuji","family":"Yonekura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Horikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiro","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2018.11.044_bib1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaci.2013.11.002","article-title":"Present state of Japanese cedar pollinosis: the national affliction","volume":"133","author":"Yamada","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bib2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S1081-1206(10)63532-6","article-title":"Epidemiology of Japanese cedar pollinosis throughout Japan","volume":"91","author":"Okuda","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000084256","article-title":"Increasing prevalence of Japanese cedar pollinosis: a meta-regression analysis","volume":"136","author":"Kaneko","year":"2005","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2332\/allergolint.08-RAI-0074","article-title":"Present situation of cedar pollinosis in Japan and its immune responses","volume":"58","author":"Okamoto","year":"2009","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2018.11.044_bib5","first-page":"1","article-title":"Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27-29 1997","volume":"53","year":"1998","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.11.044_bib6","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1398-9995.2007.01451.x","article-title":"Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study","volume":"62","author":"Jacobsen","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.11.044_bib7","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S1081-1206(10)60211-6","article-title":"Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study","volume":"101","author":"Marogna","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bib8","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jaci.2010.08.030","article-title":"Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study","volume":"126","author":"Marogna","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1398-9995.2007.01620.x","article-title":"Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)","volume":"63","author":"Bousquet","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.11.044_bib10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jaci.2017.06.014","article-title":"Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy","volume":"141","author":"Valovirta","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13601-015-0057-8","article-title":"Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score","volume":"5","author":"Didier","year":"2015","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2018.11.044_bib12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.alit.2016.11.001","article-title":"Japanese guidelines for allergic rhinitis 2017","volume":"66","author":"Okubo","year":"2017","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2018.11.044_bib13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000479693","article-title":"Bioavailability of house dust mite allergens in sublingual allergy tablets is highly dependent on the formulation","volume":"174","author":"Ohashi-Doi","year":"2017","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2332\/allergolint.46.135","article-title":"A\u00a0basic policy for allergen standardization in our country and standardization of Japanese cedar (Cryptomeria japonica) pollen extracts","volume":"46","author":"Yasueda","year":"1997","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2018.11.044_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000381059","article-title":"Efficacy and safety of sublingual immunotherapy for two seasons in patients with Japanese cedar pollinosis","volume":"166","author":"Okamoto","year":"2015","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bib16","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/00016480510026944","article-title":"Comparative study of two Japanese rhinoconjunctivitis quality-of-life questionnaires","volume":"125","author":"Okuda","year":"2005","journal-title":"Acta Otolaryngol"},{"key":"10.1016\/j.jaip.2018.11.044_bib17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jaip.2016.11.009","article-title":"World Allergy Organization systemic allergic reaction grading system: is a modification needed?","volume":"5","author":"Cox","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2018.11.044_bib18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jaci.2013.03.039","article-title":"Grading local side effects of sublingual immunotherapy for respiratory allergy","volume":"132","author":"Passalacqua","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bib19","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1398-9995.2009.02041.x","article-title":"\u2018Well days\u2019 after sublingual immunotherapy with a high-dose 6-grass pollen preparation","volume":"64","author":"Worm","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.11.044_bib20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1398-9995.2010.02434.x","article-title":"Days with severe symptoms: an additional efficacy endpoint in immunotherapy trials","volume":"66","author":"Durham","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.11.044_bib21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/WOX.0b013e3181c6c379","article-title":"Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009","volume":"2","author":"Canonica","year":"2009","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2018.11.044_bib25","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jaci.2006.05.003","article-title":"Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis","volume":"118","author":"Dahl","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bib26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaci.2010.11.035","article-title":"Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults","volume":"127","author":"Nelson","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bib27","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.jaci.2012.08.032","article-title":"Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE","volume":"130","author":"Cox","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bib28","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jaci.2015.06.036","article-title":"Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized, double-blind, placebo-controlled phase III trial","volume":"137","author":"Demoly","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bib29","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.jaci.2016.09.043","article-title":"Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis","volume":"139","author":"Okubo","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bib30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jaci.2009.10.035","article-title":"Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet","volume":"125","author":"Durham","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bib31","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jaci.2011.12.973","article-title":"SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial","volume":"129","author":"Durham","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bib32","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/cea.12100","article-title":"Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis","volume":"43","author":"Didier","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2018.11.044_bib33","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/jama.2016.21040","article-title":"Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: the GRASS randomized clinical trial","volume":"317","author":"Scadding","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2018.11.044_bib34","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jaci.2007.07.046","article-title":"Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis","volume":"120","author":"Didier","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bib35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1398-9995.2005.00949.x","article-title":"Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis","volume":"61","author":"Dahl","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.11.044_bib36","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaci.2010.11.034","article-title":"Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents","volume":"127","author":"Blaiss","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bib37","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jaci.2014.03.019","article-title":"Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Mosbech","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bibE1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000381059","article-title":"Efficacy and safety of sublingual immunotherapy for two seasons in patients with Japanese cedar pollinosis","volume":"166","author":"Okamoto","year":"2015","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2018.11.044_bibE2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.2517-6161.1954.tb00159.x","article-title":"Some problems in interval estimation","volume":"16","author":"Fieller","year":"1954","journal-title":"J\u00a0Roy Stat Soc B"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818308183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818308183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:18:04Z","timestamp":1761974284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219818308183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S2213219818308183"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2018.11.044","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Efficacy and Dose-Finding Trial of Japanese Cedar Pollen Sublingual Immunotherapy Tablet","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2018.11.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}